Ivermectin B1a

CAT: 0804-HY-126937-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-126937-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Ivermectin B1a, a derivative of Avermectin B1a (HY-15308), is a main component of Ivermectin (HY-15310) [1]. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19[2].
CAS Number
[71827-03-7]
UNSPSC
12352005
Hazard Statement
H301
Target
Parasite; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/ivermectin-b1a.html
Purity
99.97
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C/C([C@H]([C@H](/C=C/C=C1CO[C@]([H])([C@@H](C(C)=C[C@]2(C3=O)[H])O)[C@@]\12O)C)O[C@]4(C[C@@H]([C@H]([C@@H](O4)C)O[C@@]5(O[C@H]([C@@H]([C@H](C5)OC)O)C)[H])OC)[H])=C\C[C@@]6(C[C@@]([H])(C[C@@]7(O6)CC[C@@H]([C@]([H])(O7)[C@@H](C)CC)C)O3)[H]
Molecular Formula
C48H74O14
Molecular Weight
875.09
Precautions
H301
References & Citations
[1]Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo) . 2017 May;70 (5) :680-684.|[2]Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19 (1) :23.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched

Related Products

CatalogName
HY-15310-01Ivermectin
HY-125729-01Ivermectin B1b
HY-15310R-01Ivermectin (Standard)
HY-W654244Ivermectin-d2
HY-15308-01Avermectin B1a
HY-N8483-01Eprinomectin B1a
HY-130349Emamectin B1a
HY-15308BΔ2-Avermectin B1a
HY-137229Avermectin B1a monosaccharide
HY-15308R-01Avermectin B1a (Standard)

Alternative Products

CatalogName
MBS385492-01Ivermectin

Popular Products